Moors & Cabot’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.4M | Buy |
307,330
+12,563
| +4% | +$329K | 0.29% | 70 |
|
|
2026
Q1 | $8.28M | Buy |
294,767
+12,344
| +4% | +$329K | 0.35% | 53 |
|
|
2025
Q4 | $7.03M | Sell |
282,423
-112,305
| -28% | -$2.83M | 0.3% | 68 |
|
|
2025
Q3 | $10.1M | Sell |
394,728
-16,614
| -4% | -$410K | 0.44% | 46 |
|
|
2025
Q2 | $9.97M | Buy |
411,342
+17,588
| +4% | +$410K | 0.46% | 44 |
|
|
2025
Q1 | $9.98M | Sell |
393,754
-8,676
| -2% | -$227K | 0.51% | 41 |
|
|
2024
Q4 | $10.7M | Sell |
402,430
-31,289
| -7% | -$849K | 0.51% | 42 |
|
|
2024
Q3 | $12.6M | Sell |
433,719
-17,463
| -4% | -$509K | 0.62% | 30 |
|
|
2024
Q2 | $12.6M | Buy |
451,182
+71,082
| +19% | +$1.96M | 0.67% | 27 |
|
|
2024
Q1 | $10.5M | Buy |
380,100
+138,492
| +57% | +$3.84M | 0.57% | 33 |
|
|
2023
Q4 | $6.96M | Sell |
241,608
-10,932
| -4% | -$330K | 0.43% | 45 |
|
|
2023
Q3 | $8.38M | Sell |
252,540
-84,147
| -25% | -$2.98M | 0.57% | 33 |
|
|
2023
Q2 | $12.3M | Sell |
336,687
-5,552
| -2% | -$216K | 0.82% | 20 |
|
|
2023
Q1 | $14M | Buy |
342,239
+1,259
| +0.4% | +$54.4K | 0.96% | 14 |
|
|
2022
Q4 | $17.5M | Sell |
340,980
-648
| -0.2% | -$31.1K | 1.22% | 10 |
|
|
2022
Q3 | $14.9M | Sell |
341,628
-5,120
| -1% | -$249K | 1.14% | 9 |
|
|
2022
Q2 | $18.2M | Sell |
346,748
-738
| -0.2% | -$37.6K | 1.31% | 9 |
|
|
2022
Q1 | $18M | Sell |
347,486
-17,778
| -5% | -$922K | 1.11% | 12 |
|
|
2021
Q4 | $21.6M | Sell |
365,264
-365,932
| -50% | -$18.1M | 1.33% | 8 |
|
|
2021
Q3 | $31.5M | Buy |
731,196
+375,173
| +105% | +$16.6M | 1.98% | 6 |
|
|
2021
Q2 | $13.9M | Buy |
356,023
+5,944
| +2% | +$231K | 0.98% | 16 |
|
|
2021
Q1 | $12.7M | Buy |
350,079
+20,647
| +6% | +$733K | 0.97% | 17 |
|
|
2020
Q4 | $12.1M | Sell |
329,432
-8,399
| -2% | -$308K | 1.02% | 15 |
|
|
2020
Q3 | $11.8M | Buy |
337,831
+60,266
| +22% | +$2.11M | 1.11% | 14 |
|
|
2020
Q2 | $8.61M | Buy |
277,565
+68,207
| +33% | +$2.32M | 0.92% | 19 |
|
|
2020
Q1 | $6.48M | Sell |
209,358
-28,767
| -12% | -$980K | 0.94% | 19 |
|
|
2019
Q4 | $8.89M | Buy |
238,125
+658
| +0.3% | +$23.4K | 0.89% | 21 |
|
|
2019
Q3 | $8.1M | Buy |
237,467
+16,409
| +7% | +$597K | 0.89% | 21 |
|
|
2019
Q2 | $9.09M | Buy |
221,058
+16,901
| +8% | +$671K | 1.15% | 16 |
|
|
2019
Q1 | $8.21M | Sell |
204,157
-2,639
| -1% | -$106K | 1.12% | 17 |
|
|
2018
Q4 | $8.58M | Sell |
206,796
-19,860
| -9% | -$824K | 1.35% | 10 |
|
|
2018
Q3 | $9.47M | Buy |
226,656
+4,345
| +2% | +$167K | 1.16% | 13 |
|
|
2018
Q2 | $7.64M | Sell |
222,311
-9,245
| -4% | -$316K | 1.03% | 16 |
|
|
2018
Q1 | $7.8M | Buy |
231,556
+5,505
| +2% | +$189K | 1.03% | 16 |
|
|
2017
Q4 | $7.75M | Buy |
226,051
+18,077
| +9% | +$616K | 1.03% | 13 |
|
|
2017
Q3 | $7.05M | Buy |
207,974
+15,009
| +8% | +$482K | 1.02% | 14 |
|
|
2017
Q2 | $6.16M | Buy |
192,965
+1,860
| +1% | +$58.7K | 1.02% | 14 |
|
|
2017
Q1 | $6.19M | Sell |
191,105
-14,101
| -7% | -$445K | 1.05% | 11 |
|
|
2016
Q4 | $6.3M | Buy |
205,206
+10,556
| +5% | +$322K | 1.04% | 14 |
|
|
2016
Q3 | $6.26M | Buy |
194,650
+9,751
| +5% | +$326K | 1.05% | 12 |
|
|
2016
Q2 | $6.19M | Sell |
184,899
-3,357
| -2% | -$107K | 1.09% | 13 |
|
|
2016
Q1 | $5.3M | Buy |
188,256
+1,854
| +1% | +$53K | 0.96% | 15 |
|
|
2015
Q4 | $5.7M | Buy |
186,402
+187
| +0.1% | +$5.88K | 1.04% | 12 |
|
|
2015
Q3 | $5.54M | Sell |
186,215
-2,356
| -1% | -$75.5K | 1.02% | 11 |
|
|
2015
Q2 | $6.01M | Sell |
188,571
-3,882
| -2% | -$127K | 0.98% | 15 |
|
|
2015
Q1 | $6.34M | Sell |
192,453
-8,424
| -4% | -$268K | 1.06% | 14 |
|
|
2014
Q4 | $5.93M | Sell |
200,877
-6,074
| -3% | -$174K | 1.01% | 15 |
|
|
2014
Q3 | $5.82M | Buy |
206,951
+3,047
| +1% | +$85.5K | 0.99% | 15 |
|
|
2014
Q2 | $5.75M | Buy |
203,904
+29,618
| +17% | +$844K | 0.97% | 15 |
|
|
2014
Q1 | $5.31M | Buy |
+174,286
| New | +$5.2M | 1.34% | 12 |
|
Other funds holding PFE
Moors & Cabot's PFE Position: Q2 2026 in Review
Moors & Cabot increased its Pfizer (PFE) stake by 4.3% in Q2 2026, buying an estimated $329K and bringing the position to 307,330 shares worth $7.4M. The position accounts for 0.29% of the portfolio, ranked #70.
Moors & Cabot first reported a position in PFE in Q1 2014 and has held it in 50 quarters since. The position peaked at $31.5M in Q3 2021. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Moors & Cabot held 307,330 shares of Pfizer worth $7.4M as of Q2 2026.
- Moors & Cabot bought 12,563 Pfizer shares in Q2 2026, an estimated $329K.
- Pfizer made up 0.29% of Moors & Cabot's portfolio in Q2 2026, its #70 holding.
- Moors & Cabot first reported a position in Pfizer in Q1 2014 and has held it in 50 quarters since.
- Moors & Cabot's Pfizer position peaked at $31.5M in Q3 2021.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.